Rigel’s R348 Fails in Phase II Study, Shares Down 13.6% – Analyst Blog
Rigel Pharmaceuticals, Inc. ( RIGL ) announced that its ophthalmic JAK SYK inhibitor, R348, failed to meet the primary and …read more
Rigel Pharmaceuticals, Inc. ( RIGL ) announced that its ophthalmic JAK SYK inhibitor, R348, failed to meet the primary and …read more
Brazil’s state run energy giant, Petroleo Brasileiro S.A. or Petrobras ( PBR ) announced that it has made a fourth …read more
King Digital Entertainment plc ( KING ) reported second quarter fiscal 2014 earnings of 52 cents per share, which managed …read more
Occidental Petroleum is a premier oil and gas producer. It’s reaping huge rewards from the energy boom taking place in …read more
Though Intel Corporation is one of the world’s most successful technology companies, the slowdown of the PC market over the …read more
By Ben Levine for Kapitall. It’s been a big month for the global pharmaceutical industry. As of Monday, pharmaceutical giant …read more
Graphene, a nano scale wonder material, is one of the hottest areas of materials science research. Discovered in 2004 by …read more
Strong pickup sales helped power Ford’s turnaround. They could also power one of the next phases of Ford’s growth. Source …read more
Today’s article profiles McDonald’s (MCD), the world’s leading fast food chain. The company has had its ups and downs this year, however, according to the… Read More »The Golden Arches May Be A Good Buy
If you’re under 30 and already planning for your financial future, you’re ahead of the pack. Basically, at this point …read more